Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial. by Hinchliffe, Robert & Powell, J T
                          Hinchliffe, R., & Powell, J. T. (2017). Comparative clinical effectiveness and
cost effectiveness of endovascular strategy v open repair for ruptured
abdominal aortic aneurysm: three year results of the IMPROVE randomised
trial. BMJ, 359. https://doi.org/10.1136/bmj.j4859
Publisher's PDF, also known as Version of record
Link to published version (if available):
10.1136/bmj.j4859
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ at
https://research-information.bris.ac.uk/pure/files/153484464/Improve_3_year_BMJ.pdf . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
the bmj | BMJ 2017;359:j4859 | doi: 10.1136/bmj.j4859 1
RESEARCH
Comparative clinical effectiveness and cost effectiveness of  
endovascular strategy v open repair for ruptured abdominal  
aortic aneurysm: three year results of the IMPROVE 
 randomised trial
IMPROVE Trial Investigators
ABSTRACT
OBJECTIVE
To assess the three year clinical outcomes and cost 
effectiveness of a strategy of endovascular repair 
(if aortic morphology is suitable, open repair if not) 
versus open repair for patients with suspected 
ruptured abdominal aortic aneurysm.
DESIGN
Randomised controlled trial.
SETTING
30 vascular centres (29 in UK, one in Canada),  
2009-16.
PARTICIPANTS
613 eligible patients (480 men) with a clinical 
diagnosis of ruptured aneurysm, of whom 502 
underwent emergency repair for rupture.
INTERVENTIONS
316 patients were randomised to an endovascular 
strategy (275 with confirmed rupture) and 297 to open 
repair (261 with confirmed rupture).
MAIN OUTCOME MEASURES
Mortality, with reinterventions after aneurysm repair, 
quality of life, and hospital costs to three years as 
secondary measures.
RESULTS
The maximum follow-up for mortality was 7.1 years, 
with two patients in each group lost to follow-up by 
three years. After similar mortality by 90 days, in the 
mid-term (three months to three years) there were 
fewer deaths in the endovascular than the open repair 
group (hazard ratio 0.57, 95% confidence interval 
0.36 to 0.90), leading to lower mortality at three years 
(48% v 56%), but by seven years mortality was about 
60% in each group (hazard ratio 0.92, 0.75 to 1.13). 
Results for the 502 patients with repaired ruptures 
were more pronounced: three year mortality was lower 
in the endovascular strategy group (42% v 54%; odds 
ratio 0.62, 0.43 to 0.88), but after seven years there 
was no clear difference between the groups (hazard 
ratio 0.86, 0.68 to 1.08). Reintervention rates up to 
three years were not significantly different between 
the randomised groups (hazard ratio 1.02, 0.79 to 
1.32); the initial rapid rate of reinterventions was 
followed by a much slower mid-term reintervention 
rate in both groups. The early higher average quality 
of life in the endovascular strategy versus open repair 
group, coupled with the lower mortality at three 
years, led to a gain in average quality adjusted life 
years (QALYs) at three years of 0.17 (95% confidence 
interval 0.00 to 0.33). The endovascular strategy 
group spent fewer days in hospital and had lower 
average costs of −£2605 (95% confidence interval 
−£5966 to £702) (about €2813; $3439). The 
probability that the endovascular strategy is cost 
effective was >90% at all levels of willingness to pay 
for a QALY gain.
CONCLUSIONS
At three years, compared with open repair, an 
endovascular strategy for suspected ruptured 
abdominal aortic aneurysm was associated with a 
survival advantage, a gain in QALYs, similar levels of 
reintervention, and reduced costs, and this strategy 
was cost effective. These findings support the 
increasing use of an endovascular strategy, with wider 
availability of emergency endovascular repair.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN48334791; 
ClinicalTrials NCT00746122.
Introduction
Ruptured abdominal aortic aneurysm remains a 
common vascular emergency with high mortality rates. 
There have been three recent European randomised 
trials of endovascular versus open repair for ruptured 
aneurysm, including the IMPROVE trial. None of the 
individual trials or their combined data showed a 
significant survival benefit during the acute period 
(0-90 days) with endovascular repair.1-3 This challenges 
the data from systematic reviews of observational 
studies, which show a much lower operative mortality 
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WhAT IS AlReAdy knoWn on ThIS TopIC
The overall mortality associated with ruptured abdominal aortic aneurysm 
remains high
Individual patient data meta-analysis of three recent European randomised 
trials has shown that the use of keyhole endovascular repair (compared with 
traditional open repair) does not reduce the high acute mortality (0-90 days) 
from emergency surgery
WhAT ThIS STudy AddS
This is the first randomised trial comparing the use of the keyhole endovascular 
aneurysm repair versus traditional open surgery with comprehensive mid-term 
outcomes, including reinterventions, quality of life, costs, and evaluation of cost 
effectiveness
A combination of mid-term survival advantage with early gains in quality of life 
led, after three years, to significantly higher QALYs in the endovascular strategy 
group, which was achieved without an excess of reinterventions and further 
hospital costs
An endovascular strategy (endovascular repair when morphologically feasible) is 
both clinically effective and cost effective and should be adopted more widely
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after endovascular aneurysm repair (EVAR).4 5 Few 
recent comparative studies have followed patients 
undergoing either EVAR or open repair for ruptured 
abdominal aortic aneurysm in the mid or longer term 
(beyond a year after rupture). Studies, including one 
from the Vascular Study Group of New England,6 one 
from the Amsterdam cohort with ruptured aneurysm,7 
and a comparison of an endovascular first strategy 
with an open repair first strategy in Sweden,8 were 
mainly non-randomised and retrospective and could 
be confounded by aortic morphology9 and other 
unmeasured factors. Such data have suggested that, 
after three to five years, survival was similar for those 
having endovascular and open repair and that patients’ 
comorbidities and shock on admission were the main 
determinants of longer term survival.6 The Amsterdam 
cohort study, which was dominated by open repair 
patients, showed that any early survival benefit of 
EVAR had been eroded by two years, and thereafter 
survival was similar in patients treated by open or 
endovascular repair, with about 50% of patients 
remaining alive at three years.7 The Amsterdam study 
also showed that, for those discharged alive, later 
reinterventions were more common after endovascular 
than open repair. Therefore, the mid-term clinical and 
cost effectiveness of EVAR or an endovascular strategy 
for the management of ruptured aneurysm remains 
uncertain.
There has been considerable reorganisation of 
vascular services to provide higher volume centres for 
elective surgery in the UK and elsewhere.10 Further 
changes might be necessary to optimise the use of scarce 
resources, including intensive care, and to ensure 
equitable access to complex emergency surgery.11 
The logistics of providing an endovascular service for 
ruptured abdominal aortic aneurysm are considerable 
with regard to the availability of appropriate staff, 
facilities, and consumables, and many centres in the 
IMPROVE trial could not offer this service every day 
of the week. Better evidence is required to stimulate 
organisational change, particularly further evidence 
of the effect of an endovascular strategy on mortality, 
reintervention rates, health related quality of life (QoL), 
and cost beyond one year follow-up. We investigated 
the hypothesis that in the mid-term (by three years) an 
endovascular strategy remains both clinically effective 
and cost effective.
Methods
Design
IMPROVE (ISRCTN 48334791) was a multicentre trial 
of unselected patients aged over 50 in whom a senior 
hospital clinician had made a clinical diagnosis of 
ruptured aortic aneurysm. Patients were randomised to 
either an endovascular strategy (immediate computed 
tomography and emergency EVAR if morphologically 
feasible) or emergency open repair. Patients were 
usually randomised in the emergency room, before 
computed tomography and anaesthesiology opinion. 
Therefore, open repair was the specified treatment 
for patients who were morphologically unsuitable 
for EVAR in the endovascular strategy group. In the 
open repair group, computed tomography was not 
compulsory but was used in 90% of patients. The trial 
methods, 30 day, and one year outcomes have been 
published elsewhere.2 12 Soon after the completion of 
recruitment in 2013, with the observation that about 
50% patients remained alive at three years, the trial 
was extended to provide three year outcomes for all 
patients. The same outcomes collected at one year 
were collected at three years, on a post hoc basis, as 
three year outcomes were not originally registered at 
the start of the trial because further funding for longer 
term follow-up could be sought only once all patients 
had been recruited. The study protocol was updated in 
August 2013 to include the three year outcomes: this, 
and the statistical analysis plans, are available from 
the trial websites (www.improvetrial.org and www.
imperial.ac.uk/medicine/improvetrial).
Centres, randomisation, and patients
This trial was conducted in 29 British and one Canadian 
centres with proved competence in emergency EVAR. 
An independent contractor provided central telephone 
computer generated randomisation (1:1), stratified by 
centre with variable block size, which automatically 
provided date and time of randomisation. There was 
no blinding. The study randomised 613 patients from 
September 2009 to July 2013 and followed them 
up to July 2016. The trial guidelines for suitability 
for EVAR were aneurysm neck diameter ≤32 mm, 
aneurysm neck length ≥10 mm, and neck angulation 
<60°.13 As the radiological diagnosis of rupture can 
be difficult,14 experts in a core laboratory based at St 
George’s Hospital, London, later reviewed computed 
tomograms.
Outcomes
The primary outcome was total mortality, with 
secondary outcomes at three years including 
reinterventions related to the aneurysm, QoL, resource 
use, costs, quality adjusted life years (QALYs), and 
incremental cost effectiveness. Total mortality in the 
UK was from data linkage with the Office for National 
Statistics (ONS) and locally in Canada. Trained local 
coordinators were responsible for the collection of 
prospective data on resource use including readmissions 
and reinterventions related to the aneurysm and its 
repair and QoL data using EuroQol questionnaire (five 
dimension, three level version; EQ-5D) for all patients 
undergoing aneurysm repair. Related reinterventions 
were categorised as arterial, related to laparotomy, 
or other and classified according to whether they 
were for a life threatening condition or not (table A in 
appendix 1). The completeness of reintervention and 
readmission data was verified by detailed audit in 
Scotland and Canada and additionally cross checked 
against an administrative dataset (hospital episode 
statistics) for reinterventions in England, including 
those at non-trial hospitals (the source of data used 
for analyses is shown in table B in appendix 1). The 
main metric of cost effectiveness was the incremental 
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net monetary benefits, which is calculated by valuing 
incremental QALYs at a recommended threshold 
of £30 000 (€33 650, $39 540) per QALY, and then 
subtracting the incremental costs.15 The endovascular 
strategy would be judged relatively cost effective if 
the estimated incremental net monetary benefit was 
positive at this threshold, but we also considered a 
range of alternative thresholds.
Patient involvement
Patients who had survived an earlier repair of ruptured 
aneurysm and their families were involved in the 
design of the trial and choice of outcomes (particularly 
the two stage ethical approval, reporting of place of 
discharge from hospital, and adverse reinterventions). 
The wife of a previous patient was included in the trial 
steering committee to oversee the conduct of the trial. 
Patients were not involved in the recruitment process. 
Patients’ quality of life was assessed at three time 
points. A short animated video about the trial and its 
results is available for patients and the public at www.
improvetrial.org and will be made available to the 
Circulation Foundation.
Statistical analysis
Analyses of the full trial cohort were performed on 
an intention to treat basis. Mortality was assessed 
with standard survival analysis techniques, including 
Kaplan-Meier curves and Cox proportional hazard 
models, with all available follow-up and additionally 
for the time periods 0-three months (acute) and 
three months to three years (mid-term). Primary 
analyses were unadjusted for baseline variables with 
secondary analyses adjusted for sex, age (continuous 
measure), Hardman index16 (morbidity score), lowest 
systolic blood pressure, and aneurysm neck length 
(when appropriate). We used multiple imputation 
with chained equations to account for missing data 
for baseline covariates, resource use, costs, and the 
EQ-5D utility score (further details are in table C in 
appendix 1.17 All adjustment variables except age were 
also used for subgroup analysis but, given the multiple 
tests performed, an interaction test P value of <0.01 
was required to claim strong evidence of differences 
between subgroups. The prespecified analysis plan 
also identified a principal sensitivity analysis restricted 
to the 502 patients with a confirmed diagnosis of 
rupture in whom repair was started. In this analysis 
data were analysed according to the group assigned at 
randomisation. We compared the proportion surviving 
at three years after randomisation between the 
randomised groups using a Pearson’s χ2 test without 
continuity correction and reported odds ratios using 
logistic regression. Hazard ratios corresponding to time 
to first reintervention related to the aneurysm and time 
to any reinterventions related to the aneurysm and its 
repair were obtained from Cox regression models, the 
latter with a multiple failure time model.18
We calculated the EQ-5D utility index score by 
combining the EQ-5D health profile of each patient 
with health state preference values from the UK 
general population19 and compared the resultant mean 
QoL utility scores with unpaired t tests. For patients 
discharged without aneurysm repair, quality of life was 
estimated as previously12 (further details in appendix 
2). QALYs up to three years were calculated by valuing 
each patient’s survival time by their QoL at three, 12, 
and 36 months according to the “area under the curve” 
method.20 Detailed resource use and costs within three 
years of randomisation were measured in accordance 
with international guidelines21 and reported from a 
hospital and personal social services perspective as 
recommended by the UK National Institute for Health 
and Care Excellence (NICE).15 The costs and QALYs 
after one year were discounted at 3.5% per year.19
Costs were initially calculated in £ and converted into 
€. The incremental QALYs and costs were estimated 
with a seemingly unrelated regression (SUR) model,22 
and, like the primary analysis of the clinical outcomes, 
this was without adjustment for baseline covariates. 
The estimate of incremental costs and QALYs were 
then used to report incremental net monetary benefits 
of the endovascular strategy according to the overall 
intention to treat population.
Given the moderate rates of non-compliance with 
trial protocol, and that the non-compliance was not 
at random, we also applied a complier average causal 
effects (CACE) model. The CACE estimate reports 
the potential effect of adhering to trial protocol—
endovascular strategy (EVAR if morphologically 
feasible) or open repair—to provide a less biased 
estimate of the true causal effect of an endovascular 
strategy than a per protocol analysis.23  24 The 
CACE approach estimates the causal effects of an 
endovascular first strategy versus an open repair 
strategy among those patients who would have 
complied with the trial protocol for either strategy. 
Analyses were conducted in the 502 patients with 
treated ruptures and the CACE estimates for all 
endpoints, including the incremental net monetary 
benefits, were reported alongside the intention to treat 
odds ratio or mean difference in this population at 
three years (further details in appendix 2).
Results
Study population and interventions
The study population has been described previously.2 
Figure 1 shows the 613 randomised patients followed-
up to three years after randomisation. Briefly, among 
the 316 patients in the endovascular strategy 
group, 275 had aorto-iliac aneurysm rupture, eight 
had acute symptomatic intact aneurysm, 27 had 
asymptomatic abdominal aortic aneurysm with other 
acute diagnoses, and six had other diagnoses. Of the 
300/316 who underwent computed tomography, 186 
(62%) were considered morphologically suitable for 
EVAR. Among the 297 patients in the open repair 
group, 261 had aorto-iliac aneurysm rupture, 14 
had acute symptomatic intact aneurysm, 19 had 
asymptomatic abdominal aortic aneurysm with other 
acute diagnoses, and three had other diagnoses. In 
total 536 patients had blood breaching the aneurysm 
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sac (rupture): 34 died before repair and repair was 
started in 502 (group for principal sensitivity analysis), 
259 and 243 in the endovascular strategy and open 
repair groups, respectively. In 149/259 EVAR was 
started, and 110/259 patients underwent open 
repair (26 against protocol, mainly because a staffed 
endovascular suite was not immediately available). In 
the open repair group, 33 patients underwent EVAR 
(mainly because they were poor candidates for general 
anaesthesia). Between 30 days and three years, two 
patients in each randomised group emigrated and 
were lost to follow-up. At randomisation, the mean 
age was 77, 22% of the patients were women, and the 
mean aneurysm diameter was 8.4 cm. The baseline 
characteristics of the 502 treated ruptures, according 
to randomisation status, were similar to those of the 
full trial cohort (table 1).
Primary outcome: mortality
The mean follow-up for mortality was 4.9 years 
(median 4.7; range 0.1-7.1 years) with 2.5 mean 
person years of observation (to death or censoring). 
There were 179 deaths in the endovascular strategy 
group and 183 deaths in the open repair group 
(table 2). The hazard ratio was 0.92 (95% confidence 
interval 0.75 to 1.13; P=0.41), with similar results 
for mortality related to aneurysm (0.89, 0.69 to 1.16; 
P=0.41) and after adjustment (table D in appendix 1). 
Kaplan-Meier survival curves (fig 2) showed a slight 
divergence after the acute phase, with lower mortality 
in the endovascular strategy group between three 
months and three years (0.57, 0.36 to 0.90; P=0.015), 
before converging by seven years. The increased 
number of deaths in the open repair group between 
three months and three years was not related to the 
aneurysm (table 2; table D in appendix 1). Subgroup 
analysis suggested that the endovascular strategy 
might be more effective in reducing mortality in 
women than in men (fig A in appendix 3). By three 
years, 151 (48%) and 165 (56%) patients had died 
in the endovascular strategy and open repair groups, 
respectively (odds ratio 0.73, 95% confidence interval 
0.53 to 1.00; P=0.053), and the mean life years were 
1.72 and 1.61 (P=0.31).
The Kaplan-Meier curves for the principal sensitivity 
analysis of 502 treated ruptures followed a similar 
Table 1 | Baseline characteristics of patients with ruptured abdominal aortic aneurysm randomised to treatment with endovascular strategy 
(endovascular repair if aortic morphology is suitable, open repair if not) or open repair. Figures are numbers (percentage) unless stated otherwise*
Variable Endovascular strategy (n=316) Open repair (n=297)
Rupture repairs
Endovascular strategy (n=259) Open repair (n=243)
Mean (SD) age (years) 76.7 (7.4) 76.7 (7.8) 76.0 (7.4) 76.2 (7.6)
Men 246 (78) 234 (79) 209 (81) 195 (80)
Women 70 (22) 63 (21) 50 (19) 48 (20)
Mean (SD) blood pressure on admission (mm Hg):
 Systolic 110.3 (32.9) 110.5 (31.2) 108.7 (33.1) 109.0 (31.1)
 Diastolic 65.3 (21.4) 66.7 (22.5) 65.1 (22.0) 65.3 (22.7)
Hardman index (0-5):
 0 93 (33) 71 (28) 83 (36) 60 (28)
 1 130 (46) 124 (48) 103 (44) 97 (46)
 2 46 (16) 48 (19) 36 (15) 43 (20)
 3 11 (4) 12 (5) 9 (4) 10 (5)
 4 2 (1) 2 (1) 2 (1) 2 (1)
 5 0 (0) 0 (0) 0 (0) 0 (0)
Computed tomography performed:
 Yes 305 (97) 265 (89) 251 (97) 216 (89)
 No 11 (3) 32 (11) 8 (3) 27 (11)
Mean (SD) maximum aortic diameter (cm)† 8.5 (1.9) 8.3 (1.8) 8.7 (1.7) 8.4 (1.8)
Mean (SD) neck length (mm) — — 24 (17) 23 (16)
Median time (IQR) to repair‡ (min) — — 47 (28-73) 37 (22-62)
IQR=interquartile range.
*Of 502 in whom rupture repairs was started, data missing for 9 for admission blood pressure, 57 for Hardman index, 68 for maximum aortic diameter, 91 for neck length (91).
†Measured by core laboratory. 
‡From randomisation to theatre admission
Open repair (n=297)
Patients with known vital status (n=295)
Ruptured aneurysm (n=261):
  Died before repair (n=18)
  Repair started (n=243)†
Eligible for 3 year follow-up (n=110)
EQ-5D completed: 91/105‡ (87%)
Endovascular strategy (n=316)
Randomised (n=613)
Incomplete follow-up (n=133):
  Lost to follow-up between
    31 and 90 days (n=2)
  Died within 90 days (n=93)
  Died 3 months to 3 years (n=38)
Symptomatic AAA (n=14)
Other diagnosis (n=22) 
Died by 3 years (n=16/36)
Patients with known vital status (n=314)
Ruptured aneurysm (n=275):
  Died before repair (n=16)
  Repair started (n=259)*
Eligible for 3 year follow-up (n=148)
EQ-5D completed: 117/143‡ (82%)
 Incomplete follow-up (n=111):
  Lost to follow-up aer 1 year
    (n=2)
  Died within 90 days (n=91)
  Died 3 months to 3 years (n=18)
Symptomatic AAA (n=8)
Other diagnosis (n=33) 
Died by 3 years (n=26/41)
Fig 1 | Flow of patients to three years after randomisation. *Includes 26 patients who 
had open repairs in breach of protocol; †includes 33 patients who had EVARs in breach 
of protocol; ‡five patients per randomised group withdrew consent for being contacted 
about completing EQ-5D questionnaires but allowed their other data to be used. 
Completion rates reported indicate fully completed questionnaires
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pattern to the full cohort (fig 2). The overall hazard 
ratio was 0.86 (95% confidence interval 0.68 to 1.08; 
P=0.19), which remained similar after adjustment. 
By three years, 109/259 (42%) and 131/243 (54%) 
from the endovascular strategy and open repair 
groups, respectively, had died (odds ratio 0.62, 95% 
confidence interval 0.43 to 0.88; P=0.008). The odds 
ratio for a compliers average causal effects (CACE) 
model was 0.53 (0.34 to 0.84; P=0.008). A post hoc 
analysis showed that the sex difference was stronger 
in this subgroup, particularly for deaths related to the 
aneurysm (hazard ratio 0.44 (95% confidence interval 
0.24 to 0.81) in women and 1.09 (0.79 to 1.52) in men; 
P=0.01 for interaction).
Secondary outcomes
Reinterventions related to aneurysm
Among the 502 treated ruptures, 230 reinterventions 
related to the aneurysm were recorded within three years 
of randomisation; 121 and 109 in the endovascular 
strategy and open repair groups respectively (hazard 
ratio 1.02, 95% confidence interval 0.79 to 1.32; 
P=0.88). The reinterventions, categorised by whether 
they were arterial, related to laparotomy or other, or 
for a life threatening condition are shown in table E in 
appendix 1. Overall and by time (acute 0-three months 
or three months to three years) the reintervention 
rates were similar between those randomised to an 
endovascular strategy and those randomised to open 
repair, with about 28% of each group needing at least 
one reintervention related to the aneurysm. Figure 3 
shows the cumulative incidences for patients with at 
least one intervention to three years and at least one 
intervention for a life threatening condition (see also 
table A in appendix 1). New reinterventions for life 
threatening conditions continued to occur at a much 
slower but steady rate between three months and 
three years in both groups. The hazard ratios for risk 
of reintervention, both overall and by time, remained 
similar after adjustment (table F in appendix 1). The 
indications for mid-term reintervention (both related 
to the aneurysm and other, by both randomised group 
and treatment received) between three months and 
three years are shown in table G in appendix 1: 21% 
of surviving patients treated with EVAR had a mid-
term intervention. Patients and their families ranked 
amputation as the most adverse reintervention. There 
were eight amputations within the first three years, five 
in the endovascular strategy group and three in the 
open repair group, but seven of these occurred after 
open repair.
Quality of life, QALYs, costs, and cost effectiveness
The average QoL was higher in the endovascular 
strategy group in the first year but by three years was 
similar across the randomised groups (fig 4). Table 3 
shows QALYs, costs, and cost effectiveness for the full 
intention to treat population (n=613). The QALY gain 
at three years for the endovascular strategy group was 
0.166 (95% confidence interval 0.002 to 0.331) and 
was higher for women and those with highest baseline 
Hardman index but was otherwise similar across 
subgroups (table H in appendix 1). Resource use up 
to three years after randomisation, related to primary 
Table 2 | Causes of death in patients randomised to treatment with endovascular strategy (endovascular repair if aortic 
morphology is suitable, open repair if not) or open repair by group by time period for all randomised patients (n=613)
Endovascular strategy (n=316) Open repair (n=297) Unadjusted hazard ratio (95% CI) P value
All follow-up
Related to the aneurysm 112 120 0.92 (0.75 to 1.13) 0.41
Cardiovascular 26 23
Pulmonary 13 15
Cancer 19 13
Other 9 12
Total 179 183
0-3 months
Related to the aneurysm 104 112 0.98 (0.76 to 1.26) 0.88
Cardiovascular 8 3
Pulmonary 5 0
Cancer 1 0
Other 2 3
Total 120 118
3 months-3 years
Related to the aneurysm 5 5 0.57 (0.36 to 0.90) 0.015
Cardiovascular 12 16
Pulmonary 5 10
Cancer 7 10
Other 2 6
Total 31 47
>3 years
Related to the aneurysm 3 3 1.44 (0.80 to 2.62) 0.23
Cardiovascular 6 4
Pulmonary 3 5
Cancer 11 3
Other 5 3
Total 28 18
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admission and readmissions related to the aneurysm, 
including those for reinterventions, are detailed in table 
I in appendix 1. Overall, patients in the endovascular 
strategy stayed, on average, fewer days in hospital than 
those in the open repair group; the mean total days in 
hospital was 14.4 versus 20.5, with an overall cost 
reduction of −£2605 (95% confidence interval −£5966 
to £702) (−€2816, −€6425 to €794).
When the incremental costs and QALYs were 
represented on the cost effectiveness plane, most 
(88%) estimates were in the quadrant showing the 
endovascular strategy as “dominant,” with lower 
mean costs and higher mean QALYs (fig 5). The 
incremental net monetary benefit of the endovascular 
strategy versus open repair (QALY valued at £30 000) 
was positive at £7367 (95% confidence interval 
£1829 to £13 454) (€7956, €1930 to €14 530), a 
finding robust to a range of assumptions, and was 
similar across subgroups (see table H in appendix 
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n=262) at 3 years
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Fig 3 | Cumulative incidence of reinterventions in 502 
patients in whom repair of rupture was started. Gray’s 
test for testing equality of cumulative incidence curves: 
P=0.643 for time to first reintervention; P=0.713 for 
time to reintervention for life threatening condition 
(included hindquarter amputation, colectomy with stoma 
for mesenteric or colonic ischaemia, graft infection, 
secondary rupture, and repeat aneurysm repairs (full list 
in table A in appendix 1)
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1 and fig B in appendix 3). The probability that the 
endovascular strategy is more cost effective is above 
90% across all willingness to pay thresholds for a 
QALY gain (fig 6).
We repeated all the above analyses for the 502 
patients with confirmed rupture in whom repair was 
started using both an intention to treat and CACE 
approach (table 4). Overall, mean differences in EQ-
5D, QALYs, and total cost for these patients according 
to intention to treat were similar to those reported 
for the full trial cohort (n=613, table 3). In addition 
to the significant differences in mortality and QALYs, 
CACE analysis led to larger differences in the cost 
effectiveness endpoints between treatment groups: 
the mean incremental net monetary benefit of the 
endovascular strategy versus open repair was £21 528 
(95% confidence interval £5999 to £37 057), almost 
three times higher than for the full trial cohort and the 
QALY gains also increased markedly.
discussion
This is the first randomised comparison of 
interventions for ruptured abdominal aortic aneurysm 
with comprehensive mid-term (three year) reporting. 
We found that after aneurysm rupture an endovascular 
strategy offers no significant reduction in operative 
mortality at 30 or 90 days, but there is an interim mid-
term survival advantage (three months to three years), 
which, together with the early gains in quality of life, 
leads to a mid-term gain in QALYs after three years. 
Reinterventions related to the aneurysm, particularly 
those for life threatening conditions, occurred at 
a similar rate in both groups. The cost differences 
observed at 30 days (non-significantly in favour of the 
endovascular strategy group)2 were not eroded by an 
increased burden of reinterventions in later follow-
up, and therefore the endovascular strategy is cost 
effective. All these results are in sharp contrast with 
those of earlier trials conducted in the elective setting 
(table 5).
To deal with criticisms about the pragmatic design 
of the trial, we also report analyses (both causal and 
intention to treat) for the 502 patients in whom repair 
of rupture was started, which emphasise the survival 
benefit, QALY gain, and cost effectiveness of the 
endovascular strategy over three years.
Interpretation
The reasons for these mid-term differences between the 
comparative effectiveness of an endovascular strategy 
and open repair in the emergency and elective settings 
remain speculative. The shock associated with rupture 
probably kills many patients irrespective of the type of 
repair, but EVAR is less invasive and can be conducted 
under local anaesthesia so that patients recover more 
rapidly than after open repair.
Acute kidney injury is common after repair of a 
ruptured aneurysm, particularly open repair, and has 
prolonged consequence for mortality.32-34 Acute kidney 
injury was not formally documented, but 46 patients in 
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Table 3 | Quality adjusted life years (QALYs), costs, and cost effectiveness at three years for all patients (n=613) randomised to treatment with 
endovascular strategy (endovascular repair if aortic morphology is suitable, open repair if not). Results are reported after multiple imputation
Endovascular strategy Open repair
Mean difference (95% CI) P valueNo of patients Mean (SD) No of patients Mean (SD)
Life years 316 1.72 (1.43) 297 1.61 (1.41) 0.115 (−0.110 to 0.341) 0.314
QALYs* 316 1.14 (1.03) 297 0.97 (1.02) 0.166 (0.002 to 0.331) 0.048
Total cost (£) 316 16 878 (19 624) 297 19 483 (22 412) −2605 (−5966 to 702) 0.120
Incremental net benefit (£)† — — — — 7637 (1820 to 13 454) 0.005
*Includes patients who died and those without proved rupture, who were assumed to have, on average, same quality of life of elective repair patients.12 QALYs between 1 and 3 years 
discounted with NICE’s recommended discount rate of 3.5%.
†Incremental net benefit for endovascular versus open repair calculated by multiplying mean difference in QALY by NICE’s recommended willingness to pay threshold (£30 000 per QALY gain) 
and subtracting from this incremental cost.
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the open repair group with confirmed rupture required 
renal replacement therapy postoperatively versus 32 
in the endovascular strategy group, suggesting that 
this might have contributed to the better three year 
outcomes in the endovascular strategy group. Patients 
in the open repair group had longer stays in critical 
care than the endovascular strategy group (average 
6.3 versus 4.2 days), and there is some evidence that 
prolonged stay in critical care is associated with higher 
long term mortality.35
The proportion of women in the IMPROVE trial (22%) 
was much higher than in the trials of elective aneurysm 
repair, and the advantages of the endovascular 
strategy were possibly greater in women than in 
men. The continuing burden of major reinterventions 
related to laparotomy after open repair for ruptures 
(not seen, or not reported, after elective open repair) 
might contribute to mid-term costs in the open repair 
group, while endovascular devices and the technical 
skills to deploy them might have improved since the 
trials of elective repair. The convergence of the survival 
curves beyond three years is unexplained too, but this 
phenomenon also has been observed in the analysis 
of recent registry data and an earlier analysis from 
Medicare.6 36
Strengths and limitations
This study has several limitations. Firstly, this was 
a pragmatic trial in the emergency setting and not 
all randomised patients (with a clinical diagnosis 
of rupture) had a ruptured aneurysm, although 
99% did have an aneurysm. Secondly, some of the 
patients with ruptured aneurysm died before repair 
(similar numbers in each randomised group), and in 
this emergency setting the non-compliance rate was 
higher than anticipated (about 10% in each group). 
Thirdly, though this is by far the largest of the three 
recent European trials, with hindsight the sample size 
might have been larger to allow for non-compliance. 
Fourthly, after 30 days follow-up focused mainly on 
the group of 502 patients in whom repair of a ruptured 
aneurysm was started. Such patients, however, are 
the clinically most relevant group and were analysed 
both by intention to treat and complier average causal 
estimates for all outcomes. Fifthly, after the acute 
period, data on reinterventions were limited only to 
those related to the aneurysm and its repair; however, 
these data were complete, including procedures 
related to the aneurysm at hospitals outside the trial. 
Finally, as there was no blinding it also is possible that 
patients who received EVAR might have reported better 
quality at early time points.
There also are several strengths to this study. 
Firstly, recruitment was non-selective, and over half 
the potentially eligible patients at the trial centres 
were randomised,2 increasing the generalisability 
of the findings. Secondly, it is the first prospective 
randomised study with complete clinical and health 
economic mid-term follow-up. Thirdly, few patients 
were lost to follow-up, and data completion rates were 
excellent.
Summary
This mid-term follow-up provides convincing support 
for the benefits of an endovascular strategy (EVAR if 
morphologically feasible) versus open repair to treat 
Table 4 | Three year outcomes for principal sensitivity analysis of 502 patients with confirmed diagnosis of abdominal aortic aneurysm rupture in 
whom repair was started. Figures are mean differences unless stated otherwise
Outcome (measure)
No of patients
Estimate (95% CI)
P value*As randomised (intention to treat) Complier average causal effect (CACE)
OR for mortality† 498 0.62 (0.43 to 0.88) 0.53 (0.34 to 0.84) 0.008
OR for any reintervention related to the aneurysm 502 1.12 (0.76 to 1.65) 1.16 (0.69 to 1.94) 0.58
EQ-5D‡ 262 0.013 (−0.069 to 0.096) 0.041 (−0.112 to 0.193) 0.75
QALYs§ 502 0.229 (0.043 to 0.414) 0.512 (0.084 to 0.940) 0.016
Total cost (£) 502 −2610 (−6200 to 978) −6126 (−14336 to 2083) 0.154
Incremental net benefit (£) 502 9484 (2828 to 16 140) 21 528 (5999 to 37 057) 0.003
OR=odds ratio.
*Same for intention to treat and CACE estimates, but magnitude of effect might be different.
†4 patients lost to follow-up for mortality by 3 years.
‡For EQ-5D-3L scores, number of patients is total number eligible for follow-up (that is, still alive and not lost to follow-up). EQ-5D missing for 33 (22%) EVAR patients and 21 (19%) open repair 
patients.
§Includes patients who died.
Table 5 | Comparison of mid-term health outcomes from randomised trials of endovascular versus open repair for elective and ruptured 
abdominal aortic aneurysm repair
Parameter Elective repair Rupture repair from IMPROVE trial
30 day mortality 2.5-fold higher for open repair25 No difference2
3 year mortality No difference25 Endovascular strategy better
Length of primary hospital stay No difference26 27 Shorter for endovascular strategy12
Reintervention rate 2-3-fold higher after EVAR25 27 28 No difference
Quality of life Better after open repair or no difference at 1 year27 29 Better at 3 months, 1 year for endovascular strategy
Costs EVAR higher27 30 Endovascular strategy less
Cost effectiveness EVAR not cost effective27 30 31 Endovascular strategy cost effective
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patients with ruptured abdominal aortic aneurysm. 
At three years, the endovascular strategy offers an 
increase in QALYs, without an excess of reinterventions, 
and is cost effective.
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